Ignite Creation Date:
2025-12-25 @ 12:02 AM
Ignite Modification Date:
2026-01-01 @ 9:19 PM
Study NCT ID:
NCT05550558
Status:
NOT_YET_RECRUITING
Last Update Posted:
2022-09-28
First Post:
2022-09-20
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Camrelizumab Plus Anlotinib in Patients With Recurrent Sporadic MMRd Endometrial Cancer
Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Endometrial Cancer | View |
Keywords: